Twelve organizations spanning gene editing science, clinical medicine, manufacturing, regulatory strategy, and patient advocacy aim to deliver first-in-human trial within three years.
By adapting virus-like particles to carry the machinery for a type of gene editing called prime editing, scientists have corrected disease-causing mutations in animals and increased editing efficiency.